To whom should I refer a patient with pyoderma for further evaluation and treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Referral for Pyoderma Gangrenosum

Patients with pyoderma gangrenosum should be referred to a dermatologist for diagnosis and management, with additional consultation from gastroenterology or rheumatology if underlying systemic disease is suspected.

Primary Referral: Dermatology

  • Dermatology consultation is essential for establishing the diagnosis of pyoderma gangrenosum, as this is a diagnosis of exclusion requiring expertise in differentiating it from other ulcerative conditions 1, 2
  • Most patients with pyoderma gangrenosum are eventually referred to dermatology, though often after significant delay—in one series, 80% were not referred during the initial phase of disease 3
  • The dermatologist will coordinate local and systemic treatment, which typically requires aggressive immunosuppressive therapy 4

Secondary Referrals Based on Associated Conditions

Gastroenterology Referral

  • Refer to gastroenterology if inflammatory bowel disease is suspected, as ulcerative colitis is the most common associated systemic disease (occurring in approximately 33% of cases) 3, 2
  • Pyoderma gangrenosum frequently appears during flare-ups of ulcerative colitis or Crohn's disease 3
  • Gastroenterology involvement is particularly important because TNF-α inhibitors like infliximab have the best evidence for efficacy in patients with concomitant inflammatory bowel disease 5

Rheumatology Referral

  • Consider rheumatology consultation if inflammatory arthritis is present, as various forms of inflammatory arthritis are among the common systemic associations 2
  • Approximately 50% of pyoderma gangrenosum patients have underlying systemic diseases that may require rheumatologic evaluation 2

Vascular Surgery Referral

  • Refer to vascular surgery experienced with pyoderma gangrenosum for leg ulcers, particularly when associated with deep vein thrombosis or obliterative vasculitis causing arterial ischemia 6
  • Leg ulcers in pyoderma gangrenosum may require debridement or specialized wound care that necessitates surgical expertise 6

Age-Specific Considerations

  • For patients aged 20-40 years, screening for concomitant systemic disease is essential 3
  • This age group has higher likelihood of associated inflammatory bowel disease or hematologic disorders 3

Common Pitfalls to Avoid

  • Do not delay dermatology referral—early specialist involvement improves outcomes, yet most patients experience significant diagnostic delays when managed initially by non-dermatologists 3
  • Avoid treating as simple infection without specialist input—pyoderma gangrenosum can worsen with surgical debridement due to pathergy (worsening at sites of trauma) 2
  • The most common referring specialties are gastroenterology and general surgery, often after prolonged unsuccessful treatment attempts 3

References

Research

Pyoderma gangrenosum: an update.

Rheumatic diseases clinics of North America, 2007

Research

Pyoderma gangrenosum: classification and management.

Journal of the American Academy of Dermatology, 1996

Research

Treatment options for pyoderma gangrenosum.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2017

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is a practical approach to treating pyoderma gangrenosum in the absence of infliximab (chimeric monoclonal antibody against tumor necrosis factor-alpha)?
What does severe pyoderma gangrenosum of the legs look like?
What is the initial treatment for pyoderma gangrenosum?
What is the initial management approach for a patient presenting with Pyoderma gangrenosum (PG)?
Is the pathergy test a reliable diagnostic tool for pyoderma gangrenosum?
Can Janumet (sitagliptin and metformin) 50/500 be taken once daily?
What is the next best step in managing a 51-year-old female with a history of multisubstance abuse, partial thyroid ablation, splenomegaly (enlarged spleen), multifocal lymphadenopathy (lymph node enlargement), thrombocytopenia (low platelet count), and elevated lactate dehydrogenase (LDH), with concerns for a lymphoproliferative disorder, including lymphoma?
What is the recommended treatment regimen for a patient with Helicobacter pylori (H. pylori) infection?
What are the risks and recommendations for using Vraylar (cariprazine) in pregnant women or those planning to become pregnant?
What is the recommended treatment for an adult with unresolved URI symptoms, including sinus drainage and Eustachian tube inflammation, conjunctivitis-like symptoms, and a productive cough, similar to symptoms in a toddler and relative effectively treated with erythromycin ophthalmic and amoxicillin?
What is a suitable alternative to metformin for a patient with diabetes who is already taking glipizide (a sulfonylurea)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.